Q linea AB Market Cap ($30.38 Million)
Market Cap & Net Worth: Q linea AB (QLINEA)
Q linea AB market cap. Q linea AB (ST:QLINEA) has a market capitalization of $30.38 Million (Skr282.34 Million) as of November 5, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #23538 globally and #444 in its home market, demonstrating a -2.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Q linea AB's stock price Skr14.90 by its total outstanding shares 18948752 (18.95 Million). Also see Q linea AB operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Q linea AB Market Cap History (2018–2026)
Q linea AB market cap history from 2018 to 2026. Data shows change from $123.37 Million to $30.38 Million (-17.36% CAGR). Check Q linea AB stock quote for real-time trading data and today's change.
Q linea AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Q linea AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Q linea AB net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.58x
Q linea AB's market cap is 4.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $123.37 Million | $1.07 Million | -$128.35 Million | 115.73x | N/A |
| 2019 | $117.25 Million | $1.00 Million | -$178.06 Million | 116.67x | N/A |
| 2020 | $346.66 Million | $243.00K | -$220.19 Million | 1426.59x | N/A |
| 2021 | $230.43 Million | $9.34 Million | -$233.18 Million | 24.68x | N/A |
| 2022 | $21.41 Million | $12.79 Million | -$275.77 Million | 1.67x | N/A |
| 2023 | $7.54 Million | $4.44 Million | -$229.37 Million | 1.70x | N/A |
| 2024 | $1.41 Million | $2.36 Million | -$216.87 Million | 0.60x | N/A |
| 2025 | $50.86 Million | $11.10 Million | -$182.49 Million | 4.58x | N/A |
Competitor Companies of QLINEA by Market Capitalization
Companies near Q linea AB in the global market cap rankings as of November 5, 2026. Also see QLINEA total asset value for a full breakdown of the balance sheet.
Key companies related to Q linea AB by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #107 globally with a market cap of $196.11 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #182 globally with a market cap of $130.04 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #225 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #237 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #107 | Abbott Laboratories | NYSE:ABT | $196.11 Billion | $115.51 |
| #182 | Stryker Corporation | NYSE:SYK | $130.04 Billion | $339.65 |
| #225 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $104.96 |
| #237 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Q linea AB (2018–2026)
Market capitalization of Q linea AB from 2018 to today. Between 2018 and today, Q linea AB's market cap moved from $123.37 Million to $ 30.38 Million, with a yearly change of -17.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr30.38 Million | -40.26% |
| 2025 | Skr50.86 Million | +3514.49% |
| 2024 | Skr1.41 Million | -81.35% |
| 2023 | Skr7.54 Million | -64.76% |
| 2022 | Skr21.41 Million | -90.71% |
| 2021 | Skr230.43 Million | -33.53% |
| 2020 | Skr346.66 Million | +195.65% |
| 2019 | Skr117.25 Million | -4.96% |
| 2018 | Skr123.37 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Q linea AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $30.38 Million USD |
| MoneyControl | $30.38 Million USD |
| MarketWatch | $30.38 Million USD |
| marketcap.company | $30.38 Million USD |
| Reuters | $30.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Q linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disp… Read more